Evidence map›Paper›PMID 40779150›Full record

SynthesisClinical & translational oncology : official publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico2026

Use of PD-1/PD-L1 inhibitors in non-small cell lung cancer in elderly patients: a meta-analysis and systematic review of randomized clinical trials.

Ana Paula Bedin, Gabriela de Castro Neves Carmo Maffezolli, Luis Henrique Rios Moreira Rego, Maria Isadora Rodrigues Carlos, Pedro Henrique Albuquerque da Silva, Francisco Cezar Aquino de Moraes

Abstract readMeta-AnalysisSystematic Review
PubMed Publisher
In one paragraph

Synthesis in Clinical & translational oncology : official publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors.

Ana Paula BedinMunicipal University of São Caetano do Sul, São Paulo, 01327-000, Brazil. ana-paula-bedin@hotmail.com.ORCID http://orcid.org/0000-0003-4464-6236
Gabriela de Castro Neves Carmo MaffezolliFaculty of Medical Sciences of Santos, Santos, 11015-101, Brazil.ORCID http://orcid.org/0009-0004-5351-3229
Luis Henrique Rios Moreira RegoState University of Piauí, Teresina, 64018-030, Brazil.ORCID http://orcid.org/0009-0003-1604-6759
Maria Isadora Rodrigues CarlosPontifical Catholic University of São Paulo, Sorocaba, 18030-070, Brazil.ORCID http://orcid.org/0009-0004-0012-2777
Pedro Henrique Albuquerque da SilvaFederal University of Santa Catarina, Florianópolis, 88040-460, Brazil.ORCID http://orcid.org/0009-0009-2454-3097
Francisco Cezar Aquino de MoraesFederal University of Pará, Belém, 66073-005, Brazil.ORCID http://orcid.org/0000-0003-0623-8135

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundNon-small cell lung cancer (NSCLC) is prevalent and often diagnosed at advanced stages. Immune checkpoint inhibitors targeting PD-1/PD-L1 pathways have transformed treatment, yet elderly patients remain underrepresented in clinical trials.

methodsWe conducted a systematic review and meta-analysis of randomized clinical trials (RCTs) comparing PD-1/PD-L1 inhibitors with placebo and/or chemotherapy in elderly patients with NSCLC. Overall survival (OS), Event-Free Survival (EFS) and OS for large studies were evaluated. Random-effects model with 95% confidence intervals were applied.

resultsTwelve RCTs with 3078 patients were included. PD-1/PD-L1 inhibitors significantly improved OS (HR 0.76; 95% CI 0.69-0.84; p < 0.001) and EFS (HR 0.67; 95% CI 0.54-0.83; p < 0.001). Large studies showed consistent benefit.

conclusionsPD-1/PD-L1 inhibitors significantly improve clinical outcomes in elderly NSCLC patients compared to standard treatments.

Indexed as

B7-H1 AntigenCarcinoma, Non-Small-Cell LungImmune Checkpoint InhibitorsLung NeoplasmsProgrammed Cell Death 1 ReceptorAgedHumansRandomized Controlled Trials as TopicB7-H1 AntigenCD274 protein, humanImmune Checkpoint InhibitorsPDCD1 protein, humanProgrammed Cell Death 1 ReceptorElderly patientsMeta-analysisNon-Small cell lung cancerPD-1/PD-L1

Identifiers

PMID40779150

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.